British Journal of Cancer - Volume 94, issue 7

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras neque tellus, ornare vel pulvinar luctus, vestibulum malesuada ante. Nullam pellentesque, ipsum vel fermentum tincidunt, velit neque molestie lacus, at iaculis purus mauris in nisl. Nullam vehicula imperdiet auctor. Mauris tempus, leo eget euismod condimentum, erat justo vehicula augue, vitae ornare elit felis nec libero. Etiam et quam sit amet metus dignissim dictum sed vitae purus. Phasellus gravida hendrerit risus vitae euismod. In elementum massa facilisis nulla pulvinar at pharetra leo pellentesque.

Electronic ISSN
1532-1827
Print ISSN
0007-0920

Abstract

HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MBC) patients treated with high-dose chemotherapy (HDC). HER-2 status is also a predictive factor and when trastuzumab is administered in combination with or sequentially to chemotherapy, a significa

Journal: British Journal of Cancer, vol. 94, no. 7, 2006